Evaluation of a neurokinin-1 antagonist in preventing multiple-day cisplatin-induced nausea and vomiting
To perform a prospective non-randomized comparison of the effectiveness and safety of combined neurokinin-1 antagonist aprepitant treatment with the standard multiple-day cisplatin regimen for the prevention of cisplatin-induced nausea and vomiting (CINV).
Main Authors: | Li Quanfu, Wang Wenjuan, Chen Gang, Deng Shuqin, Jiang Caihong, Chen Feng, Zhao Jun, Li Hui, Bai Xiaojun, Hu Yuliang, Da Lenggaowa, Wu Yungaowa, Jin Gaowa |
---|---|
Format: | Article |
Language: | English |
Published: |
De Gruyter
2018-03-01
|
Series: | Open Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1515/med-2018-0005 |
Similar Items
-
A randomized trial evaluating the association between related gene polymorphism and nausea and vomiting induced by cisplatin multi-day chemotherapy
by: Yilan Jin, et al.
Published: (2023-11-01) -
Curative Effect of Aprepitant Preventing CINV
by: Shasha GUAN, et al.
Published: (2018-10-01) -
Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
by: Laurent Zelek, et al.
Published: (2023-08-01) -
Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3‐day aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study
by: Jianhua Chang, et al.
Published: (2020-07-01) -
Efficacy of the oral neurokinin-1 receptor antagonist aprepitant administered with ondansetron for the prevention of postoperative nausea and vomiting
by: Chae Seong Lim, et al.
Published: (2013-03-01)